Abstract
Derived from the structure of 1H,3H-thiazolo[3,4-a]benzimidazoles (TBZs), 2,3-diaryl-1,3-thiazolidin-4-one derivatives became a novel class of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Under the guidance of continuous structureactivity relationship (SAR) analysis and molecular modeling, various structural modifications were carried out on nearly all the positions of the thiazolidin-4-one nucleus. Some of the derivatives proved to be highly effective against HIV-1 replication at 10–40 nanomolar concentration ranges with minimal cytotoxicities. In this article, the whole development of 2,3-diaryl-1,3-thiazolidin-4-one series from the discoveries to recent advances, their panoramic SAR studies and binding modes based on molecular modeling were reviewed, and also some enlightenments for further investigation were presented.
Keywords: HIV, AIDS, 1, 3-Thiazolidin-4-ones, HIV-1 NNRTIs, Antiviral, Drug design
Current Medicinal Chemistry
Title:Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Volume: 19 Issue: 13
Author(s): Ye Tian, Peng Zhan, Diwakar Rai, Jiyan Zhang, Erik De Clercq and Xinyong Liu
Affiliation:
Keywords: HIV, AIDS, 1, 3-Thiazolidin-4-ones, HIV-1 NNRTIs, Antiviral, Drug design
Abstract: Derived from the structure of 1H,3H-thiazolo[3,4-a]benzimidazoles (TBZs), 2,3-diaryl-1,3-thiazolidin-4-one derivatives became a novel class of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Under the guidance of continuous structureactivity relationship (SAR) analysis and molecular modeling, various structural modifications were carried out on nearly all the positions of the thiazolidin-4-one nucleus. Some of the derivatives proved to be highly effective against HIV-1 replication at 10–40 nanomolar concentration ranges with minimal cytotoxicities. In this article, the whole development of 2,3-diaryl-1,3-thiazolidin-4-one series from the discoveries to recent advances, their panoramic SAR studies and binding modes based on molecular modeling were reviewed, and also some enlightenments for further investigation were presented.
Export Options
About this article
Cite this article as:
Tian Ye, Zhan Peng, Rai Diwakar, Zhang Jiyan, De Clercq Erik and Liu Xinyong, Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors, Current Medicinal Chemistry 2012; 19 (13) . https://dx.doi.org/10.2174/092986712800167383
DOI https://dx.doi.org/10.2174/092986712800167383 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?
Current Medicinal Chemistry Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs In-Silico Algorithms for the Screening of Possible microRNA Binding Sites and Their Interactions
Current Genomics Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Cognitive - Behavioral Therapy in Central Sensitivity Syndromes
Current Rheumatology Reviews Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Study on the Influences of Palindromes in Protein Coding Sequences on the Folding Rates of Peptide Chains
Protein & Peptide Letters Current State of Development of Genome Analysis in Livestock
Current Genomics Computational and Experimental Approaches for Modeling Gene Regulatory Networks
Current Pharmaceutical Design The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Intrinsic Disorder and Function of the HIV-1 Tat Protein
Protein & Peptide Letters Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Role of the Gut Microbiota in Age-Related Chronic Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry